Autoimmune hemolytic anemia (AIHA) is defined by increased erythrocyte turnover
mediated by autoimmune mechanisms. While corticosteroids remain first-line therapy in …

In the last decade, a deeper understanding of the pathogenesis of complement mediated
hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin …

Warm autoimmune hemolytic anemia (wAIHA) is characterized by evidence of red blood cell
(RBC) hemolysis and a direct antiglobulin test positive for IgG and sometimes complement …

Therapeutic options for rare congenital (hemoglobinopathies, membrane and enzyme
defects, congenital dyserythropoietic anemia) and acquired anemias [warm autoimmune …

In this review article we provide a critical insight into recent reports evaluating innovative
therapies for warm type autoimmune hemolytic anemia (wAIHA). Among published articles …

Introduction The direct antiglobulin test (DAT) or Coombs test is the cornerstone of the
diagnosis of autoimmune hemolytic anemia (AIHA). It can be performed by several methods …

Due to increasing concerns about environmental impact and toxicity, developing green and
sustainable methods for nanoparticle synthesis is attracting significant interest. This work …

Shear-thinning materials have held considerable promise as embolic agents due to their
capability of transition between solid and liquid state. In this study, a laponite nanoclay …

Drug-induced immune hemolytic anemia (DIHA) is rare phenomenon with an estimated
incidence of 1 per million/year [1], difficult to quantify and probably underestimated due the …

Ceftriaxone is widely used in pediatric outpatient care for its efficacy against respiratory and
digestive system infections, yet its increasing association with severe immune hemolytic …